Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: A prospective study

Annals of Oncology

Volumn 18, Issue 1, 2007, Pages 168-172

  Alexandre, J ^a,b   Rey, E ^a   Girre, V ^c   Grabar, S ^a   Tran, A ^a   Montheil, V ^a   Rabillon, F ^a   Dieras, V ^c   Jullien, V ^a   Herait P ^a   Pons, G ^a   Treluyer, J M ^a   Goldwasser, F ^a  

^a Université Paris 5 ^*  (France)

^b UNIVERSITY OF TEXAS   (United States)

^c INSTITUT CURIE   (France)

Author keywords

Cytochrome 3A; Docetaxel; Febrile neutropenia; Lymphocytopenia midazolam

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P450 3A; DOCETAXEL; FERRITIN; METHYLPREDNISOLONE; MIDAZOLAM; ONDANSETRON; STEROID;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BOLUS INJECTION; CANCER PATIENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; ENZYME ACTIVITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFLAMMATION; LUNG CANCER; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; SOLID TUMOR; UNIVARIATE ANALYSIS;

AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; FEMALE; FERRITINS; HUMANS; LYMPHOCYTE COUNT; MALE; MIDAZOLAM; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PROSPECTIVE STUDIES; RADIATION-SENSITIZING AGENTS; RISK FACTORS; TAXOIDS;

EID: 33846488113     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl321     Document Type: Article

References (23)

1. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: A systematic review of clinical data. Lancet Oncol 2005; 6 (4): 229-239.
2. Alexandre J, Bleuzen P, Bonneterre J et al. Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol 2000; 18: 562-573.
3. Urien S, Barre J, Morin C et al. Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. Invest New Drugs 1996; 14: 147-151.
4. Shou M, Martinet M, Korzekwa KR et al. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: Enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 1998; 8: 391-401.
5. Bruno R, Vivier N, Vergniol JC et al. A population pharmacokinetic model for docetaxel (taxotere): Model building and validation. J Pharmacokinet Biopharm 1996; 24: 153-172.
6. Bruno R, Hille D, Riva A et al. Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16: 187-196.
7. Hirth J, Watkins PB, Strawderman M et al. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000; 6: 1255-1258.
8. Yamamoto N, Tamura T, Kamiya Y et al. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J Clin Oncol 2000; 18: 2301-2308.
9. Goh BC, Lee SC, Wang LZ et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002; 20: 3683-3690.
10. Tisdale MJ. Cancer anorexia and cachexia. Nutrition 2001; 17: 438-442.
11. Gabay C, Kushner I. Acute-phase protein and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454.
12. Alexandre J, Gross-Goupil M, Falissard B et al. Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy. Ann Oncol 2003; 14: 36-41.
13. Lin YS, Lockwood GF, Graham MA et al. In vivo phenotyping for CYP3A by a single point determination of midazolam plasma concentration. Pharmacogenetics 2001; 11: 781-791.
14. D'Argenio DZ, Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetics. Comput Programs Biomed 1979; 9: 115-134.
15. Baille P, Bruno R, Schellens JH et al. Optimal sampling strategies for Bayesian estimation of docetaxel clearance. Clin Cancer Res 1997; 3: 1535-1538.
16. Garg MB, Ackland SP. Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine. J Chromatogr B Biomed Sci Appl 2000; 748: 383-388.
17. Martin M, Lluch A, Segui MA et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): Impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 2006; 17: 1205-1212.
18. Borg C, Ray-Coquard I, Philip I et al. CD4 lymphopenia as a risk factor for FN and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer 2004; 101: 2675-2680.
19. Blay JY, Negrier S, Combaret V et al. Serum level of interkeukin-6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res 1992; 52: 3317-3322.
20. Aggarwal S, Gollapudi S, Gupta S. Increased TNF-alpha-induced apoptosis in lymphocytes from aged humans: Changes in TNF-alpha receptor expression and activation of caspases. J Immunol 1999; 162: 2154-2161.
21. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103.
22. Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood 2002; 99: 3505-3516.
23. Slaviero KA, Clarke SJ, Rivory LP. Inflammatory response: An unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 2003; 4: 224-232.